2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Outstanding mix of clinical abstracts, including clinical trials, retrospective analysis, and molecular observations in myelofibrosis, polycythemia vera, essential thrombocythemia and other myeloid neoplasms
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2021 Real-world evidence of ruxolitinib efficacy and adverse-events in the long-term management of polycythemia vera (REAL-PV Study)

Tim Kong, MD, PhD, Myra Abbasi2, Fariha Zamir3, Neville Lee Jr, BSc, BA4, Katie Erdos, BA5, Daniel Chimin Choi, MD6, Franco Castillo Tokumori, MD7, Ellen Ritchie, MD8, Joseph Scandura, MD, PhD9, Ghaith Abu-Zeinah I, MD10
1 Weill Cornell Medicine, New York, United States
2 Weill Cornell Medicine Qatar, Ar-Rayyan, Qatar
3 Weill Cornell Medicine Qatar, Ar-Rayyan, Qatar
4 Weill Cornell Medicine, New York, United States
5 Weill Cornell Medicine, New York, United States
6 Weill Cornell Medicine, New York, United States
7 Weill Cornell Medicine, New York, United States
8 Weill Cornell Medicine, New York, United States
9 Weill Cornell Medicine, New York, United States
10 Weill Cornell Medicine, New York, United States

Polycythemia vera (PV) is a JAK2V617F-driven myeloproliferative neoplasm with erythrocytosis, increased thrombotic risk, and progression to myelofibrosis. The JAK1/2 inhibitor ruxolitinib (RUX), approved in 2014 for hydroxyurea-resistant or intolerant patients (pts) with PV, was associated with longer event-free survival compared to best available therapy in the MAJIC-PV randomized trial. Large real-world data analysis of safety and survival outcomes is important to support ongoing long-term utilization of RUX. In this real-world active-comparator study using the TriNetX global health research network, we examined Ruxolitinib Efficacy and Adverse events in the Long-term management of PV (REAL-PV) by defining drug-related adverse events (AEs), disease-related outcomes and overall survival (OS) in patients with PV treated with RUX compared to other cytoreductive drugs (non-RUX).

We identified 84,777 pts with PV, of whom 1,031 met eligibility for RUX exposure. Inclusion required RUX or non-RUX cytoreductive exposure for PV without baseline anemia or thrombocytopenia. The non-RUX group (hydroxyurea, interferon, and/or busulfan) included 4,985 pts. A 1:≤4 propensity-score match by age, sex, race, prior thrombosis, baseline hematocrit, and disease duration to treatment identified 777 RUX and 2,906 non-RUX pts with excellent balance (standardized mean difference, SMD, <0.10). Continuous and categorical variables were compared by Mann-Whitney U, Welch's t, or chi-square tests. Incidence rates were events per 100 patient-years, with Poisson rate ratios (RR) and 95% CIs. OS curves were compared by log-rank test.

At therapy initiation, median age of the total cohort (n=3,683) was 67 years (range 19–89), with 1,851 (50.3%) female, 819 (22.2%) non-white, and 2,863 (78%) high-risk (age >60 or prior thrombosis); median follow-up was 3.4 years. Mean lines of treatment were 1.7 (SD 0.61) for RUX vs 1.1 (0.22) for non-RUX (p<0.001), with median disease duration at treatment start of 1.2 vs 1.0 years. In the RUX group, 307 (40%) received RUX first-line.

Hematocrit control (HCT <45% and hemoglobin ≥10 g/dL) at 12 months among pts with baseline HCT ≥45% was higher with RUX than non-RUX (68% vs 56%, p=0.002). WBC control (<11) was similar (p=0.423), but platelet control (<450) was lower (48% vs 61%, p=0.003). Unlike MAJIC-PV, thrombotic events (venous and arterial) did not differ (RR 0.94, 95% CI 0.75–1.2). Similar to MAJIC-PV, OS did not differ (HR 1.07, 95% CI 0.88–1.30, p=0.50).

AEs at significantly higher rates in RUX versus non-RUX, and therefore possibly drug-related, included herpes zoster (RR 3.2), skin cancer (1.6), weight gain/obesity (1.5), anemia (1.5), non-skin solid cancers (1.3), and serious infections (1.3). Across all RUX-treated pts (n=1,031), 5-year cumulative incidences were 31% (anemia), 18% (thrombocytopenia), 16% (non-skin solid cancers), 11% (skin cancer), and 8.5% (herpes zoster). Onset was condition-dependent: anemia, mental health disorders, and obesity emerged early (~40% within the first year), whereas skin cancer, non-skin solid cancers, and herpes zoster accrued gradually (>50% after two years), consistent with cumulative, exposure-related risk. In an age-stratified competing-risks analysis, older pts (≥60 yrs) carried higher 5-year cumulative AE burden than younger pts (<60 yrs) (45% vs 28%), with enrichment relative to non-RUX in both groups (composite incidence rate ratio 1.54 and 1.51, respectively): anemia and herpes zoster across both age groups, with skin and non-skin solid cancers enriched in older pts.

In conclusion, the REAL-PV study provides real-world evidence supporting the HCT control, safety profile, and lack of OS benefit of RUX reported in MAJIC-PV. In contrast to MAJIC-PV, RUX was not associated with lower thrombotic event rates relative to other (non-RUX) cytoreductive therapies, potentially reflecting differences in patient selection. MAJIC-PV enrolled HU-resistant/intolerant pts (66% of BAT remained on HU), whereas REAL-PV also included first-line pts. The increased risks of herpes zoster, skin and solid cancers, weight gain/obesity, and serious infections should be weighed against benefits, including PV symptom control, particularly given the longer treatment horizon in younger pts. RUX is an effective cytoreductive with an established AE profile, but further evidence is needed to determine whether it should be implemented as long-term therapy for event-free or overall survival benefit.

Tim Kong, MD, PhD: No relevant conflicts of interest to declare.